[Phase II study of FF-705 by Clinical Cooperative Study Group]

Clinical efficacy of new fluorouridine derivative, FF-705, was studied in 108 patients with advanced malignant tumors. Partial responses were observed in 8 of 61 evaluable cases (13.1%): 4 of 9 patients with breast cancer, 1 of 19 patients with gastric cancer, 1 of 15 patients with lung cancer, 1 of 3 patients with kidney cancer and 1 of 1 patient with pancreas cancer. In the analysis of adverse effects of FF-705, gastrointestinal toxicity was major toxicity. Especially, diarrhea was observed in 41 of 108 patients (38.0%) within a total dose of 10 g shortly after drug administration.